![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Clinical Research Center (M.F.P., H.L.H., S.S.L.) and Division of Pharmacotherapy and Experimental Therapeutics (M.F.P.), University of North Carolina, Chapel Hill, North Carolina; Department of Basic Pharmaceutical Sciences, West Virginia University, Morgantown, West Virginia (R.L.H.); Department of Medicinal Chemistry, University of Washington, Seattle, Washington (A.E.R.); and Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina (D.C.Z.)
Cytochromes P450 (P450s) 3A, 2C, and 1A2 constitute the major "pieces" of the human liver P450 "pie" and account, on average, for 40, 25, and 18%, respectively, of total immunoquantified P450s (J Pharmacol Exp Ther 270:414–423, 1994). The P450 profile in the human small intestine has not been fully characterized. Therefore, microsomes prepared from mucosal scrapings from the duodenal/jejunal portion of 31 human donor small intestines were analyzed by Western blot using selective P450 antibodies. P450s 3A4, 2C9, 2C19, and 2J2 were detected in all individuals and ranged from 8.8 to 150, 2.9 to 27, <0.6 to 3.9, and <0.2 to 3.1 pmol/mg, respectively. CYP2D6 was detected in 29 individuals and ranged from <0.2 to 1.4 pmol/mg. CYP3A5 was detected readily in 11 individuals, with a range (average) of 4.9 to 25 (16) pmol/mg that represented from 3 to 50% of total CYP3A (CYP3A4 + CYP3A5) content. CYP1A1 was detected readily in three individuals, with a range (average) of 3.6 to 7.7 (5.6) pmol/mg. P450s 1A2, 2A6, 2B6, 2C8, and 2E1 were not or only faintly detected. As anticipated, average CYP3A content (50 pmol/mg) was the highest. Excluding CYP1A1, the remaining enzymes had the following rank order: 2C9 > 2C19 > 2J2 > 2D6 (8.4, 1.1, 0.9, and 0.5 pmol/mg, respectively). Analysis of a pooled preparation of the 31 donor specimens substantiated these results. In summary, as in the liver, large interindividual variation exists in the expression levels of individual P450s. On average, CYP3A and CYP2C9 represents the major pieces of the intestinal P450 pie, accounting for 80 and 15%, respectively, of total immunoquantified P450s.
This article has been cited by other articles:
|
|
 |
|
  Z. Riches, E. L. Stanley, J. C. Bloomer, and M. W. H. Coughtrie Quantitative Evaluation of the Expression and Activity of Five Major Sulfotransferases (SULTs) in Human Tissues: The SULT "Pie" Drug Metab. Dispos., November 1, 2009; 37(11): 2255 - 2261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Thorn, M. Hedeland, U. Bondesson, L. Knutson, M. Yasin, P. Dickinson, and H. Lennernas Different Effects of Ketoconazole on the Stereoselective First-Pass Metabolism of R/S-Verapamil in the Intestine and the Liver: Important for the Mechanistic Understanding of First-Pass Drug-Drug Interactions Drug Metab. Dispos., November 1, 2009; 37(11): 2186 - 2196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, M. G. Bartlett, C. A. White, S. Muralidhara, and J. V. Bruckner Presystemic Elimination of Trichloroethylene in Rats Following Environmentally Relevant Oral Exposures Drug Metab. Dispos., October 1, 2009; 37(10): 1994 - 1998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-Y. Chang, C. Chen, Z. Yang, and A. D. Rodrigues Further Assessment of 17{alpha}-Ethinyl Estradiol as an Inhibitor of Different Human Cytochrome P450 Forms in Vitro Drug Metab. Dispos., August 1, 2009; 37(8): 1667 - 1675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kumar, H. Qiu, N. Oezguen, H. Herlyn, J. R. Halpert, and L. Wojnowski Ligand Diversity of Human and Chimpanzee CYP3A4: Activation of Human CYP3A4 by Lithocholic Acid Results from Positive Selection Drug Metab. Dispos., June 1, 2009; 37(6): 1328 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Turpeinen, U. Hofmann, K. Klein, T. Murdter, M. Schwab, and U. M. Zanger A Predominate Role of CYP1A2 for the Metabolism of Nabumetone to the Active Metabolite, 6-Methoxy-2-naphthylacetic Acid, in Human Liver Microsomes Drug Metab. Dispos., May 1, 2009; 37(5): 1017 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hosohata, S. Masuda, T. Katsura, Y. Takada, T. Kaido, Y. Ogura, F. Oike, H. Egawa, S. Uemoto, and K.-i. Inui Impact of Intestinal CYP2C19 Genotypes on the Interaction between Tacrolimus and Omeprazole, but Not Lansoprazole, in Adult Living-Donor Liver Transplant Patients Drug Metab. Dispos., April 1, 2009; 37(4): 821 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-Y. Zhang, C. Fang, J. Zhang, D. Dunbar, L. Kaminsky, and X. Ding An Intestinal Epithelium-Specific Cytochrome P450 (P450) Reductase-Knockout Mouse Model: Direct Evidence for a Role of Intestinal P450s in First-Pass Clearance of Oral Nifedipine Drug Metab. Dispos., March 1, 2009; 37(3): 651 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ngo, Z. Yan, T. N. Graf, D. R. Carrizosa, A. D. M. Kashuba, E. C. Dees, N. H. Oberlies, and M. F. Paine Identification of a Cranberry Juice Product that Inhibits Enteric CYP3A-Mediated First-Pass Metabolism in Humans Drug Metab. Dispos., March 1, 2009; 37(3): 514 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Toriyabe, K. Nagata, T. Takada, Y. Aratsu, T. Matsubara, K. Yoshinari, and Y. Yamazoe Unveiling a New Essential Cis Element for the Transactivation of the CYP3A4 Gene by Xenobiotics Mol. Pharmacol., March 1, 2009; 75(3): 677 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Hutzler, L. M. Balogh, M. Zientek, V. Kumar, and T. S. Tracy Mechanism-Based Inactivation of Cytochrome P450 2C9 by Tienilic Acid and ({+/-})-Suprofen: A Comparison of Kinetics and Probe Substrate Selection Drug Metab. Dispos., January 1, 2009; 37(1): 59 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Yu, J. Qu, M. A. Felmlee, J. Cao, and X.-L. Jiang Quantitation of Human Cytochrome P450 2D6 Protein with Immunoblot and Mass Spectrometry Analysis Drug Metab. Dispos., January 1, 2009; 37(1): 170 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Deo and S. M. Bandiera Identification of Human Hepatic Cytochrome P450 Enzymes Involved in the Biotransformation of Cholic and Chenodeoxycholic Acid Drug Metab. Dispos., October 1, 2008; 36(10): 1983 - 1991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsubara, K. Yoshinari, K. Aoyama, M. Sugawara, Y. Sekiya, K. Nagata, and Y. Yamazoe Role of Vitamin D Receptor in the Lithocholic Acid-Mediated CYP3A Induction in Vitro and in Vivo Drug Metab. Dispos., October 1, 2008; 36(10): 2058 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Volak, S. Ghirmai, J. R. Cashman, and M. H. Court Curcuminoids Inhibit Multiple Human Cytochromes P450, UDP-Glucuronosyltransferase, and Sulfotransferase Enzymes, whereas Piperine Is a Relatively Selective CYP3A4 Inhibitor Drug Metab. Dispos., August 1, 2008; 36(8): 1594 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Williams, K. O. Jones, G. D. Ponsler, S. M. Lowery, E. J. Perkins, S. A. Wrighton, K. J. Ruterbories, M. Kazui, and N. A. Farid The Biotransformation of Prasugrel, a New Thienopyridine Prodrug, by the Human Carboxylesterases 1 and 2 Drug Metab. Dispos., July 1, 2008; 36(7): 1227 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Henshall, A. Galetin, A. Harrison, and J. B. Houston Comparative Analysis of CYP3A Heteroactivation by Steroid Hormones and Flavonoids in Different in Vitro Systems and Potential in Vivo Implications Drug Metab. Dispos., July 1, 2008; 36(7): 1332 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mitschke, A. Reichel, G. Fricker, and U. Moenning Characterization of Cytochrome P450 Protein Expression along the Entire Length of the Intestine of Male and Female Rats Drug Metab. Dispos., June 1, 2008; 36(6): 1039 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Minato, R. Suzuki, A. Asagarasu, T. Matsui, and M. Sato Biotransformation of 3-Amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878), a Novel 5-Hydroxytryptamine (5-HT)1A Agonist/5-HT3 Antagonist, in Human Hepatic Cytochrome P450 Enzymes Drug Metab. Dispos., May 1, 2008; 36(5): 831 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Foti and J. L. Wahlstrom CYP2C19 Inhibition: The Impact of Substrate Probe Selection on in Vitro Inhibition Profiles Drug Metab. Dispos., March 1, 2008; 36(3): 523 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Z. Wang, J. Q. Wu, A. S. Bridges, D. C. Zeldin, S. Kornbluth, R. R. Tidwell, J. E. Hall, and M. F. Paine Human Enteric Microsomal CYP4F Enzymes O-Demethylate the Antiparasitic Prodrug Pafuramidine Drug Metab. Dispos., November 1, 2007; 35(11): 2067 - 2075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. K. Walle and T. Walle Bioavailable Flavonoids: Cytochrome P450-Mediated Metabolism of Methoxyflavones Drug Metab. Dispos., November 1, 2007; 35(11): 1985 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tegude, A. Schnabel, U. M. Zanger, K. Klein, M. Eichelbaum, and O. Burk Molecular Mechanism of Basal CYP3A4 Regulation by Hepatocyte Nuclear Factor 4{alpha}: Evidence for Direct Regulation in the Intestine Drug Metab. Dispos., June 1, 2007; 35(6): 946 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Endo, M. Ban, K. Hirata, A. Yamamoto, Y. Hara, and Y. Momose Involvement of CYP2A6 in the Formation of a Novel Metabolite, 3-Hydroxypilocarpine, from Pilocarpine in Human Liver Microsomes Drug Metab. Dispos., March 1, 2007; 35(3): 476 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Medina-Diaz, G. Arteaga-Illan, M. B. de Leon, B. Cisneros, A. Sierra-Santoyo, L. Vega, F. J. Gonzalez, and G. Elizondo Pregnane X Receptor-Dependent Induction of the CYP3A4 Gene by o,p'-1,1,1,-Trichloro-2,2-Bis (p-Chlorophenyl)ethane Drug Metab. Dispos., January 1, 2007; 35(1): 95 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Galetin and J. B. Houston Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1220 - 1229. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
